Filing Details
- Accession Number:
- 0001567619-20-011730
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-04 17:40:15
- Reporting Period:
- 2020-06-02
- Accepted Time:
- 2020-06-04 17:40:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1676725 | Ideaya Biosciences Inc. | IDYA | Pharmaceutical Preparations (2834) | 474268251 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777413 | Mark Lackner | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | Svp, Head Of Biology | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-06-02 | 408 | $8.55 | 437 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-02 | 333 | $9.73 | 104 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-02 | 104 | $10.11 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $8.05 to $9.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Includes 845 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on May 29, 2020.
- This transaction was executed in multiple trades in prices ranging from $9.09 to $10.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $10.09 to $10.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.